Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Besifovir vs Tenofovir in Resistant Chronic Hepatitis B
NCT02792088Phase 3Completed
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Jul 2015
- Primary completion
- Feb 2020
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of besifovir dipivoxil maleate in Chronic Hepatitis B (CHB) (2 arms), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoint: Rate of subjects with HBV DNA undetected (< 400 copies/mL or 69 IU/mL) at 48 weeks. Started Jul 2015; status: completed.
02
Drugs
besifovir dipivoxil maleate
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02792088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792088.